Please ensure Javascript is enabled for purposes of website accessibility

Cel-Sci gets warning letter from NYSE

Cel-Sci Corp., of Vienna, Va., and Elkridge, a biotechnology company that is developing new immune system-based treatments for cancer and infectious diseases, said it has received a warning from staff of the New York Stock Exchange that its stock is in danger of being delisted due to noncompliance with the NYSE’s financial condition listing requirement.

The company said it has until Aug. 19 to maintain its listing by submitting a plan of compliance, and that it intends to submit such a plan by that date.

Cel-Sci said the noncompliance warning was based on the company’s second-quarter report for the period ended March 31, 2013.